Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab in Relapsed or Refractory Classic Hodgkin Lymphoma
NCT03722147Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Aug 2018
- Primary completion
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of penpulimab in classic Hodgkin lymphoma (cHL), sponsored by Akeso, Inc.. Started Aug 2018; status: completed.
02
Drugs
penpulimab
03
Conditions
classic Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03722147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03722147.